Radioactive therapy targets Hard-to-Treat brain cancer
NCT ID NCT06132737
First seen May 14, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests a new radioactive drug called [90Y]Y-PentixaTher for people with central nervous system (CNS) lymphoma that has returned or not responded to other treatments. About 15 participants will receive one intravenous dose at different strength levels to find the safest and most effective dose. The goal is to see if the drug can shrink tumors and control the disease, though it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Essen
RECRUITINGEssen, Germany
Contact
-
University Hospital Rechts der Isar
RECRUITINGMunich, Bavaria, 81675, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.